The Pennsylvania Society of Oncology and Hematology represents more than 200 physicians and other health care professionals who care for cancer patients. The Society is a non-profit corporation devoted to the improvement of hematologic and oncologic care of patients.

Membership in the Society is open to physicians, allied health professionals, and institutions with a demonstrated interest and involvement in the care of patients with hematologic and oncologic disorders. It is also open to residents and fellows who are actively enrolled in a full-time residency program in hematology or oncology in Pennsylvania or who are in an appropriate fellowship program. Corporate entities involved in the care and treatment of cancer patients may also become members.

The site provides resources for cancer patients, including a searchable database of Society members for those individuals seeking an oncologist, hematologist, surgical oncologist, or radiation oncologist.

The Pennsylvania Society of Oncology and Hematology is grateful to our Corporate Sponsors, whose donations help us fulfill our mission.

Dr. Moshe Chasky, Secretary/Treasurer of the PSOH Board, speaks about why he joined PSOH, and the value and friendships from colleagues he has gained from his membership.

Important Changes Coming to Novitasphere Log In Requirements

Novitas, the Medicare Administrative Contractor (MAC) for Jurisdictions H and Jurisdiction L, has announced important changes to Novitasphere, their free internet portal.

Click Here for Additional Information

Array BioPharma’s Encorafenib & Binimetinib Approved by FDA

As a member of PSOH we are sharing the following information from our Corporate Member, Array BioPharma, Inc’s recent FDA approval.

Array BioPharma Inc., is pleased to announce that the U.S. Food and Drug Administration has approved encorafenib (BRAFTOVI™) capsules, and binimetinib (MEKTOVIĀ®) tablets, as an oral combination therapy for patients with unresectable or metastatic melanoma with a BRAF V600E/K mutation as detected by an FDA-approved test. BRAFTOVI is not indicated for the treatment of patients with wild-type BRAF melanoma.

Click here to read the full press release

Full Prescribing information is available at: www.braftovimektovi.com

For additional information, please contact Bentley Boivin, Access Account Director at Array BioPharma at 518-441-8080 or email Bentley.boivin@arraybiopharma.com.


Our Corporate Members

Pennsylvania Society of Oncology and Hematology
777 East Park Drive, PO Box 8820
Harrisburg, PA 17105-8820
(717) 558-7750 phone
(717) 558-7841 fax

This website brought to you by:

Website design by Sister Webs Design Studio, where 5% of profits are donated to women's cancer funds

Our Corporate Members